DVAX

Dynavax Technologies

Stock NASDAQ – Stock Market Prices, News & Analysis

Dynavax Technologies est centrée sur le développement de vaccins adjuvants pour renforcer la réponse immunitaire contre diverses maladies.

$ 15.50
0.06 %

Dynavax Technologies

$ 15.50
0.06 %
DVAX

Dynavax Technologies est centrée sur le développement de vaccins adjuvants pour renforcer la réponse immunitaire contre diverses maladies.

Price history of Dynavax Technologies
Price history of Dynavax Technologies

Performance & Momentum

6 Months 47.90 %
1 Year 17.42 %
3 Years 40.27 %
5 Years 59.14 %

Strategic Analysis

Dynavax Technologies • 2026

Dynavax Technologies is positioned in the healthcare sector through the development of innovative vaccine adjuvants that enhance the immune response, targeting a niche market with strong potential in infectious disease prevention. Its model relies on biotechnological expertise and collaboration with pharmaceutical partners to accelerate commercialization.

Strengths
  • Highly specialized in vaccine adjuvants, combined with recognized scientific expertise
  • Solid growth supported by a portfolio of differentiated products
  • Presence in a sector experiencing strong demand, especially in the context of global health concerns
Weaknesses
  • Dependence on partnerships for commercialization and distribution
  • Exposure to regulatory risks inherent in pharmaceutical development
Momentum

Momentum is favorable, with positive medium-term dynamics and steady performance reflecting market interest in its innovations. However, the lack of recent news calls for monitoring its ability to sustain this momentum through clear pipeline progress or strategic announcements.

Similar stocks to Dynavax Technologies

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone